CoreWeave stock slumps 14% on wider-than-expected loss ahead of lockup expiration

CoreWeave's stock dropped 14% after the AI data center renter reported a wider-than-expected Q2 adjusted loss of 27 cents per share, despite revenue tripling year-over-year to $1.21 billion, surpassing forecasts. While the company raised its 2025 revenue guidance and noted strong demand from hyperscale customers, the impending IPO lock-up expiration and concerns over light capital expenditure guidance contributed to investor apprehension. This mixed performance, balancing robust top-line growth and demand against profitability challenges and potential dilution, signals near-term volatility despite long-term AI infrastructure tailwinds.

Analysis

CoreWeave's stock experienced a significant 14% decline following the release of its second-quarter results, which presented a conflicting picture of strong top-line growth against bottom-line misses and near-term structural headwinds. The AI data center provider reported an adjusted loss of 27 cents per share, wider than the 21-cent loss anticipated by analysts, triggering immediate investor concern. This was juxtaposed with impressive revenue that more than tripled year-over-year to $1.21 billion, surpassing the $1.08 billion forecast, and supported by a robust $30.1 billion revenue backlog. Despite this strong demand, evidenced by the finance chief's statement that demand outstrips supply, the market's focus was on several risk factors. These include an impending IPO lock-up expiration, which threatens to increase share supply and volatility, and potential dilution from the recent Core Scientific acquisition. Furthermore, while CoreWeave raised its 2025 revenue guidance to between $5.15 billion and $5.35 billion, some analysts noted this was not as aggressive as hoped, and Morgan Stanley highlighted a delay in capital expenditures as a point of weakness that could postpone future revenue recognition.

Key Decisions for Investors

• Investors should anticipate continued share price volatility in the near term, driven by the imminent IPO lock-up expiration and potential dilution related to the Core Scientific acquisition.
• Monitor the company's capital expenditure deployment in subsequent quarters, as the noted delay in spending is a key operational risk that could impact the timing of future revenue recognition.
• For long-term holders, the current price weakness could be weighed against the company's fundamental strengths, including its tripling year-over-year revenue, a $30.1 billion backlog, and its strategic position serving high-demand hyperscale customers in the AI sector.